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Abstract
Purpose—To assess the performance of Cepheid® Xpert MTB/RIF® (“Xpert”) and TB Biochip® 
MDR (“TB-Biochip”).
Methods—Sputum specimens from adults with presumptive tuberculosis (TB) were 
homogenized and split for (1) direct Xpert and microscopy, and (2) concentration for Xpert, 
microscopy, culture (Lowenstein-Jensen [LJ] solid media and Mycobacteria Growth Indicator 
Tube® [MGIT]), indirect drug susceptibility testing (DST) using the absolute concentration 
method and MGIT, and TB-Biochip.
Results—In total, 109 of 238 (45.8%) specimens were culture-positive for M. tuberculosis 
complex (MTBC), and of these, 67 isolates were rifampicin resistant (RIF-R) by phenotypic DST, 
and 64/67 (95.5%) were isoniazid resistant (INH-R). Compared to culture of the same specimen, a 
single direct Xpert was more sensitive for detecting MTBC (95.3%, 95% confidence interval [CI], 
90.0–98.3%) than direct (59.6%, 95% CI, 50.2–68.5%) or concentrated smear (85.3%, 95% CI, 
77.7–91.1%) or LJ culture (80.8%, 95% CI, 72.4–87.5%); specificity was 86.0% (95% CI 78.9–
91.3%). Compared with MGIT DST, Xpert correctly identified 98.2% (95% CI, 91.5–99.9%) of 
RIF-R and 95.5% (95% CI, 85.8–99.2%) of RIF-susceptible (RIF-S) specimens. In a subset of 104 
specimens, the sensitivity of TB-Biochip for MTBC detection compared to culture was 97.3% 
(95% CI, 91.0–99.5%); specificity was 78.1% (95% CI, 61.5– 89.9%). TB-Biochip correctly 
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identified 100% (95% CI, 94.2–100%) of RIF-R, 94.7% (95% CI, 76.7–99.7%) of RIF-S, 98.2% 
(95% CI, 91.4–99.9%) of INH-R, and 78.6% (95% CI, 52.1–94.2%) of INH-S specimens, 
compared to MGIT DST.
Conclusions—Xpert and Biochip were similar in accuracy for detecting MTBC and RIF 
resistance compared to conventional culture methods.
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Introduction
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis with an estimated 8.8 million new cases and 1.5 million deaths in 2010 [1]. 
Russia ranks among 22 countries in the world with the largest burden of tuberculosis, 
including one of the highest rates of drug-resistant TB [1]. According to nationwide 
surveillance data collected in 2009, 15.5% of not previously treated cases and 33.7% of 
previously treated TB cases in Russia were identified as multidrug-resistant (MDR) TB and 
rates continue to rise [2].
Rapid detection of MDR TB would be optimal for patient management but is hampered by 
the limitations and delays associated with the primary methods available for diagnosis of 
TB. Significant advances have been made in rapid and accurate diagnosis of TB and drug 
resistance with the advent of molecular methods. The TB-Biochip MDR (“TB-Biochip”) 
system (Biochip-IMB Ltd, Moscow, Russia), developed at the Engelhardt Institute of 
Molecular Biology, Russian Academy of Sciences, is based on a multiplex polymerase chain 
reaction (PCR) followed by hybridization on a platform of gel-based oligonucleotide 
microarrays (biochips) that simultaneously detects DNA specific for Mycobacterium 
tuberculosis complex (MTBC) and mutations that cause rifampicin (RIF) and isoniazid 
(INH) resistance from either culture isolates or clinical specimens in less than 12 hours 
[3,4]. It is used primarily in Russia and in neighboring countries that were part of the former 
Soviet Union. However, because TB-Biochip is labor intensive, technically demanding and 
requires specialized laboratory infrastructure, its utility is limited to reference laboratories. 
At the same time, batch-testing increases the turn-around time thereby reducing its clinical 
utility. More recently, technical progress has resulted in simplified diagnostic tools that 
overcome several drawbacks of earlier nucleic acid amplification tests (NAAT). The 
Cepheid® eXpert MTB/RIF® test (“Xpert”, Cepheid Inc., Sunnyvale, CA) is an automated 
on-demand assay that detects MTBC-specific DNA and mutations associated with RIF 
resistance directly from sputum within 2 hours. It does not require bio-containment 
infrastructure or molecular expertise to perform [5,6]. The test utilizes PCR and molecular 
beacon technology within a closed-system cartridge that integrates sample preparation, DNA 
extraction, amplification, and detection with minimal risk of contamination.
Our project aimed to (1) validate the Xpert using both unconcentrated and concentrated 
portions of a single sputum specimen by comparing results with direct and concentrated 
microscopy, conventional solid or liquid culture and indirect phenotypic drug susceptibility 
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testing (DST) methods, and (2) compare results from a subset of specimens to those 
obtained by TB-Biochip for detection of MTBC and rifampicin resistance directly from 
sputum.
Materials and Methods
Project Settings, Patients, and Specimens
Specimens were collected as part of routine medical care from patients at two sites in 
Russia: (1) the Central TB Research Institute (CTRI) of the Russian Academy of Medical 
Sciences in Moscow, where the majority of patients are referred with chronic, often drug-
resistant TB, and (2) the Regional TB Dispensary in Vladimir Oblast where both 
hospitalized and ambulatory patients from within the region are treated. Microbiology 
testing was performed at each site by its respective laboratory. Internal quality control and 
external quality assessment practices are followed by both laboratories with equally high 
performance.
Sputum samples of at least 5.0 ml were collected from consecutively evaluated adults (≥18 
years old) with presumptive or recently diagnosed pulmonary TB between July and October 
2011. Patients having received anti-TB drugs within 60 days prior to specimen collection 
were excluded. The final diagnosis, based on the clinical and radiographic findings and 
microbiology results from all specimens obtained from the patient during this illness 
episode, was assigned by a panel of physicians according to explicit clinical definitions and 
documented for each specimen. Because the purpose of this project was to evaluate Xpert 
performance in these two laboratories, results were not reported to the physician and did not 
influence patient management decisions. Upon review, the U.S. Centers for Disease Control 
and Prevention determined this evaluation to be a laboratory test validation project and not 
human subject research. The local sites in Russia relied on the CDC determination.
Laboratory Methods
After addition of 0.5 ml sterile distilled water and glass beads, each specimen was 
homogenized for 60–90 sec with a vortex unit and split into two portions (Figure 1). From 
one portion 1.0 mL was tested by Xpert and a smear prepared for Ziehl-Neelsen (ZN) 
microscopy [7]. The remaining portion (≥3 ml) was decontaminated with N-acetyl-L-
cysteine/sodium hydroxide (BBL MycoPrep; BD, Sparks, MD, USA) [7] and centrifuged at 
3,000 × g for 15 minutes. After centrifugation, the supernatant was decanted and the 
sediment was resuspended in 3.0 ml of phosphate buffered saline (pH 6.8), from which 0.5 
mL was tested with Xpert, 0.2 mL was inoculated onto Lowenstein-Jensen (LJ), 0.5 mL 
onto BACTEC Mycobacteria Growth Indicator Tube® (MGIT) 960 system (Becton 
Dickinson [BD], Sparks, MD, USA) culture media, and a smear prepared for auramine-
rhodamine fluorescence microscopy [7].
Smears were scored using the World Health Organization scale [8]. Acid-fast bacillus (AFB) 
positive cultures were confirmed to be MTBC by the MTBcID test (BD, Sparks, MD) [9], or 
conventional biochemical tests performed according to standard protocols [7]. For culture 
confirmation of MTBC, the CTRI laboratory also employed a real-time PCR assay using 
Kurbatova et al. Page 3













primers directed against IS6110 followed by detection with fluorescent-labeled probes 
specific for MTBC (Amplitub-Rv, Syntol, Moscow, Russia) [10,11]. Culture-based DST 
was performed by either the BACTEC MGIT 960 [12], or the absolute concentration 
method on LJ medium [13] using standard critical concentrations of 1.0 mcg/ml and 40.0 
mcg/ml for rifampicin, and critical concentrations of 0.1 mcg/ml and 0.2 mcg/ml for 
isoniazid, respectively.
The Xpert assay was performed according to the manufacturer’s instructions. Results were 
obtained using the Xpert MTB/RIF software, version 4.0.
At the CTRI laboratory only, in addition to the above procedures, a portion of the 
resuspended sediment (0.5 mL) was also tested with the TB-Biochip assay according to the 
manufacturer’s specifications. The presence and nature of mutations were determined by 
analysis of the fluorescence intensity pattern on the chip, using a fluorescence analyzer 
equipped with Imageware software (TB-Biochip-IMB, Moscow, Russia) [3,4].
Data analysis
Data were entered in an Epi Info version 3.3.5 (CDC, Atlanta, GA) database. Statistical 
analyses were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, NC). 
Sensitivity and specificity of direct and concentrated Xpert, TB-Biochip, smear microscopy 
for MTBC detection were calculated using (1) culture positivity in the same specimen as the 
reference standard and (2) the patient’s final diagnosis (based on all available clinical, 
radiographic, as well as microbiologic information). These reference standards were applied 
to all specimens included in this evaluation. Sensitivity and specificity of direct and 
concentrated Xpert as well as TB-Biochip for detection of RIF resistance was calculated 
using as the reference standard: (1) the absolute concentration method on LJ, (2) BACTEC 
MGIT 960 result and (3) combined results of DST on LJ and MGIT when RIF resistance 
was defined as resistance by either LJ and/or MGIT DST methods, RIF susceptibility 
defined as susceptible by both LJ and MGIT methods or by either method when only results 
from one method were available.
Specimens from cases with non-tuberculous mycobacteria (NTM) were included in 
calculation of specificity of Xpert. Contaminated cultures were excluded for the Xpert assay 
and TB-Biochip sensitivity and specificity calculations.
Results
Specimens
A total of 238 specimens from 201 consecutive patients with presumptive TB were tested 
using the Xpert and conventional methods (134 in Vladimir; 104 at CTRI). Of the 238 
specimens, 109 (45.8%) were culture-positive (liquid or solid) for MTBC, 65 were direct 
smear-positive, 93 were concentrated smear-positive, and NTM were isolated from 4 
specimens (2 were M. kansasii, 1 - M. avium, and 1 - M. scrofulaceum). Of 109 culture-
positive specimens, 67 (61.5%) were found to be rifampicin-resistant by phenotypic DST, 
and 64 of these (95.5%) were also resistant to isoniazid.
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Comparison of direct Xpert assay with microscopy and culture results for detection of 
MTBC
In total, 230 of 238 (96.6%) specimens gave an interpretable result with the direct Xpert 
assay, 119 were positive, 111 were negative, and 8 (3.4%) were uninterpretable. All smear-
positive, culture-positive specimens and 88.6% (39/44) of direct smear-negative, culture-
positive specimens were identified by the direct Xpert as having MTBC DNA. A single 
direct Xpert test was more sensitive (95.3%, 102/107) than either direct (59.6%, 65/109) or 
concentrated (85.3%, 93/109) microscopy for detection of culture-positive M. tuberculosis 
complex (Table 1). Among 121 specimens with negative liquid and solid culture MTBC 
result and available direct Xpert result, 104 were MTB negative by direct Xpert, i.e. the 
specificity of direct Xpert was 86.0% (Table 1). Seventeen specimens that were culture-
negative for MTBC, tested positive by the direct Xpert assay: 11 of these 17 specimens were 
from patients who were subsequently classified as TB patients (7 based on positive 
laboratory results from specimens collected outside of the project and 4 based on their final 
diagnosis). Of the remaining 6 patients, 3 were suspected of TB relapse, and TB was ruled 
out in the other 3 patients based on clinical and bacteriological criteria. The specificity of 
direct Xpert for excluding TB was 89.3% (50 of 56) when the final diagnosis was used as 
the reference standard. None of the 4 NTM specimens were positive in the Xpert assay.
The indeterminate rate (3.4%, 8/238) for direct Xpert was lower than the MGIT 
contamination rate (4.2%, 10/238) but higher than that of solid media (2.1%, 5/236).The 
overall sensitivity of Xpert (94.5%, 103/109) was not significantly affected when 
concentrated specimens were tested, but the indeterminate rate was reduced to zero. Median 
time from specimen receipt to report of MTBC from MGIT was 10 days (interquartile range 
[IQR]: 7, 15) and 24 days (IQR: 18, 34) from LJ culture compared to same day results using 
Xpert.
Comparison of direct Xpert results with phenotypic DST results for detection of RIF 
resistance
Xpert correctly detected rifampicin resistance-associated mutations in 55 of 56 (98.2%) 
specimens when compared with MGIT results, and in 45 of 50 (90.0%) specimens when 
compared with those obtained by LJ DST. RIF resistance-associated mutations were not 
identified by Xpert in 42 of 44 (95.5%) specimens that were RIF susceptibile by MGIT and 
in 28 of 30 (93.3%) that were RIF-susceptible by LJ (Table 2). Overall concordance 
between Xpert and phenotypic methods to detect RIF resistance was 97.0% (97/100) with 
MGIT and 91.3% (73/80) with LJ. The rate of isoniazid resistance in phenotypically RIF-
resistant specimens was 95.5% (64/67). Given 98.2% sensitivity for detection of rifampicin 
resistance by Xpert compared to MGIT, 93.8% of MDR TB specimens were identified by 
the Xpert.
Of 8 specimens with discordant RIF results between Xpert and phenotypic DST, 3 had 
mutations in the rpoB gene by Xpert and were susceptibile by either culture-based method 
(Table 3). Five specimens were found not to have rpoB gene mutations by Xpert but were 
phenotypically resistant. Six of these 8 discordant isolates were further tested by TB-Biochip 
and all results coincided with the Xpert result. Median time from specimen receipt to 
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completion of phenotypic DST was 22 (IQR: 16, 30) and 52 days (IQR: 46, 64) for MGIT 
and LJ, respectively.
Performance of TB-Biochip
At the CTRI laboratory a portion of each concentrated specimen was also tested with the 
TB-Biochip assay. Of the 104 specimens tested, 71 (68.3%) were culture-positive for 
MTBC; 80.3% (57/71) were RIF-resistant and 87.3% (62/71) were INH-resistant by 
phenotypic DST. The TB-Biochip for detection of M. tuberculosis complex in culture-
positive specimens had an overall sensitivity of 97.3% (69/71), (100% [64/64] for smear-
positive, and 71.4% [5/7] for smear-negative specimens); specificity was 78.1% (25/32) in 
culture-negative specimens (Table 1).
For detection of rifampicin resistance, the sensitivity of TB-Biochip was 100% (50/50) when 
compared with MGIT DST results and 90.9% (40/44) compared with LJ results. Specificity 
was 94.7% (18/19) compared with MGIT and 92.9% (13/14) compared with LJ (Table 2). 
Of 54 phenotypically RIF-resistant, TB-Biochip mutation-positive specimens, the most 
frequent rpoB gene mutation detected by TB-Biochip was rpoB531 Ser→Leu (94.4%, 
51/54); 3 specimens had concomitant mutations in rpoB533 Leu→Pro (n=2) or 
rpoB526_His→Pro (n=1). Two specimens had rpoB511_Leu→Pro mutation, and 1 
specimen bore two mutations (rpoB516 Asp→Gly and rpoB 511 Leu→Pro). For detection of 
MTBC and RIF resistance, TB-Biochip results were 100% concordant with those obtained 
from direct and concentrated Xpert.
TB-Biochip detected mutations conferring isoniazid resistance in 98.2% (54/55) 
phenotypically INH-resistant specimens by MGIT and 97.8% (44/45) by LJ. TB-Biochip did 
not detect INH resistance-conferring mutations in 78.6% (11/14) of INH-susceptible 
specimens by MGIT and 84.6% (11/13) by LJ, respectively. Of 61 phenotypically INH-
resistant, TB-Biochip mutation-positive specimens, a specific mutation in the katG gene 
(315 Ser→Thr) was detected in the majority of specimens (98.4%, 60/61) and 11/61 
(18.0%) specimens had a concomitant mutation in the inhA gene (5 inhA15C→T and 6 
inhA8T→G). A concomitant mutation in the intergenic region between ahpC and oxyR 
genes AhpC10 C→T was detected in 1 specimen. For one other specimen, the only mutation 
associated with resistance to INH was in the intergenic region between ahpC and oxyR 
genes AhpC10 C→T. There were no indeterminate test results for TB-Biochip.
Discussion
We validated the Xpert assay in two clinical laboratories in Russia where the rate of 
tuberculosis and proportion of drug resistance is relatively high, using single, pre-processed 
sputum specimens that were homogenized and split for testing by Xpert and conventional 
methods. For those specimens received at the CTRI laboratory, Xpert was also compared 
with TB-Biochip, an assay developed in Russia, using conventional laboratory methods as a 
reference standard.
A recent meta-analysis by Chang et al. [14], including results from 18 unique studies and 
10,224 pulmonary specimens of TB suspects, estimated Xpert sensitivity for detection of M. 
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tuberculosis complex to be 90.4% (95%CI 89.2%–91.4%), ranging from 73%–74% [15,16] 
to 98%–100% [5,17] across studies depending on the study population. In our project, using 
culture positivity (liquid or solid) as the reference standard, the sensitivity of Xpert was 
95.3% for detection of MTBC when tests were performed directly from unprocessed 
sputum, and 94.5% when a concentrated portion of the same specimen was tested, similar to 
findings reported by Boehme et al. [5]. Interestingly, the indeterminate rate dropped from 
3.4% to 0% when concentrated specimens were tested. Others have speculated that the 
higher viscosity of unprocessed sputum may contribute to the indeterminate results when 
these types of specimens are tested with Xpert [18]. The direct Xpert test was more sensitive 
(95.3%) than direct smear (59.6%), concentrated smear (85.3%) or LJ culture (80.8%), 
identifying 88.6% of direct smear-negative, culture-positive specimens.
In the same meta-analysis [14], the pooled specificity for MTBC detection was 98.4% 
(95%CI 98.0%–98.7%). In our project, the direct Xpert had lower specificity for excluding 
MTBC (86.0%) when compared with the culture result from the same specimen. Specificity 
of the direct Xpert for exclusion of TB, however, was 89.3% when compared with a 
combined reference standard that included all available microbiology and radiography 
results as well as the patient’s final diagnosis. Among the 6 specimens with direct Xpert-
positive results from patients with active TB ruled out, 3 were from patients who completed 
treatment for TB in the past. The presence of residual DNA from nonviable organisms in the 
specimen or a sub-clinical relapse, in which the bacillary burden was very low, could 
explain the positive results [14]. Complete specimen homogeneity may not have been 
achieved after processing with glass beads and prior to removing a portion for direct Xpert, 
resulting in Xpert-positive, culture-negative findings. Furthermore, delays in transport, 
additional sample decontamination using NaOH or suboptimal culture conditions for 
resistant and/or unfit bacilli could have affected organism viability and growth in culture. 
False Xpert-positive results of the remaining 3 specimens are unexplained. It is well 
established that falsely positive NAAT results from amplicon contamination or cross-
reaction with other species can occur [19,20]. However, these possible explanations are 
unlikely since Xpert has multiple features that may reduce false positive results such as its 
analytical specificity based on the molecular probe design, its closed cartridge system that 
minimizes specimen-to-specimen cross contamination and automated readout that 
minimizes user interpretation errors. Nevertheless, other possible causes such as specimen 
contamination at the time of collection, laboratory errors (mislabeling, pipetting or clerical 
errors) or cross contamination with a strongly positive specimen during the sample 
preparation process must be considered.
A principle advantage of the Xpert is rapid detection of DNA mutations associated with 
rifampicin resistance for timely initiation of treatment with second-line drugs and prevention 
of further transmission. This is especially important in Russia where nearly all TB patients 
are hospitalized at least for the intensive phase of treatment. Chang and colleagues [14] 
reported pooled sensitivity and specificity for detecting rifampicin resistance of 94.1% and 
97.0%, respectively. However, the accuracy for detection of rifampicin resistance varied 
widely between reports, with ranges for sensitivity from 80% [21] to 97%–100% [5,6,15] 
and specificity from 72% [21] to 98%–100% [5,16,22]. In our project, concordance of direct 
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Xpert for detection of mutations associated with RIF resistance, including sensitivity 
(98.2%) and specificity (95.5%), was higher with the MGIT DST method than with the 
absolute concentration method on LJ (sensitivity 90.0% and specificity 93.3%). The 
observed discordance between the two phenotypic DST methods re-emphasizes the 
complexities and limitations of conventional growth-based DST. Because of the high 
prevalence of rifampicin resistance in our sample (61.5%), the positive predictive value for 
RIF resistance by Xpert was >95% using phenotypic DST as a reference. Consistent with 
previous reports for high MDR TB prevalence settings [23,24], we found low rates of RIF 
resistance unaccompanied by resistance to isoniazid (5%), so RIF resistance identified by 
Xpert can be a proxy for MDR TB in such populations until DST for isoniazid is completed.
TB-Biochip performed well in detecting MTBC (sensitivity 97.3%, specificity 78.1%) 
compared with culture. Specificity for excluding TB was 100% when compared with a 
combined reference standard including final diagnosis. Concordance between Xpert and TB-
Biochip was 100% for detection of MTBC. Sensitivity and specificity of TB-Biochip for 
RIF resistance was 100%, and 94.7%, respectively, when compared with MGIT DST. 
Perfect concordance between TB-Biochip and Xpert for RIF resistance-conferring mutations 
may be explained by overlapping nucleotide sequences of probes for the rpoB gene in both 
assays. Comparable to previously published data [3,25,26,27], we report sensitivity and 
specificity of 98.2% and 78.6% (compared to MGIT DST), respectively, for detection of 
INH resistance by TB-Biochip. However, TB-Biochip is a fully manual test and requires 
specialized molecular laboratory infrastructure and specialized expertise which limits use of 
this technology outside of central reference laboratories.
The incidence of tuberculosis is high and the prevalence of non-tuberculous mycobacteria 
within Russia is low. Consequently, few specimens from patients without active TB and 
with NTM were included in this study, thereby limiting calculations of specificity. Duplicate 
specimens were obtained from 37 patients; these were not analyzed separately with methods 
for correlated data. Since this validation project was restricted to sputum specimens of ≥5 
ml, the results may not apply to patients with less productive or non-productive cough. HIV 
status of project patients was not collected, but HIV co-infection among TB patients in these 
two settings is relatively low (<5%).
Despite these limitations, our project has several strengths. All tests were performed on the 
same specimen which reduced variability caused by differences between specimens from the 
same patient, and all results were interpreted by staff members who were unaware of results 
from other tests included in the project. Xpert performance for detection of MTBC was 
assessed using culture results from the same specimen as well as its performance for the 
final diagnosis based on radiography, clinical judgment and culture results from other 
specimens concurrently collected.
Based on these favorable results, the regional laboratory in Vladimir has launched a pilot 
point-of-care testing program whereby Xpert testing has been implemented at three 
microscopy centers located within the region. Broadening the testing range beyond the low 
diagnostic capability of smear microscopy, currently available at these centers, to include 
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Xpert testing may expedite diagnosis and treatment of MDR-TB and possibly become an 
important modality for improving patient care and outcomes within the region.
Conclusion
This project describes the results of an algorithm for validation of Xpert MTB/RIF used by 
two laboratories within Russia, and a comparison of a portion of those results with results 
obtained by TB-Biochip, a more technically demanding assay that requires both laboratory 
expertise and specialized facilities. Results demonstrate that a single unconcentrated sputum 
can be tested using Xpert with high sensitivity and specificity for detection of MTBC and 
RIF resistance, equivalent to those obtained with TB-Biochip. Coupled with its simplicity 
and speed, the Xpert assay addresses two major gaps in settings with a high incidence of TB, 
a high prevalence of MDR TB or limited laboratory infrastructure: rapid, accurate detection 
of MTBC and simultaneous identification of rifampicin-resistant tuberculosis. This tool is 
especially valuable in settings without the capacity for concentrating sputum, without high-
level biosafety facilities, or highly skilled laboratory staff.
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Table 1
Sensitivity and specificity in detection of MTBC by diagnostic test











N=109 N=93 N=16 N=127 b
Xpert, direct
    n/N (%) 102/107c (95.3%) 91/91c (100%) 11/16 (68.8%) 104/121d (86.0%)
    95% CI 90.0–98.3% 96.8–100% 43.7–87.5% 78.9–91.3%
Xpert, concentrated
    n/N (%) 103/109 (94.5%) 91/93 (97.9%) 12/16 (75.0%) 111/127 (87.4%)
    95% CI 88.9–97.7% 93.1–99.6% 50.1–91.5% 80.8–92.4%
Direct smear
    n/N (%) 65/109 (59.6%) 65/93 (69.9%) 0/16 (0%) 124/127 (97.6%)
    95% CI 50.2–68.5% 60.0–78.6% 0–17.1% 93.7–99.4%
Concentrated smear
    n/N (%) 93/109 (85.3%) 93/93 (100%) 0/16 (0%) 114/126g (90.5%)
    95% CI 77.7–91.1% 96.8–100% 0–17.1% 84.4–94.7%
LJ only
    n/N (%) 84/104e (80.8%) 77/89f (86.5%) 7/15g (46.7%) 125/125h (100%)
    95% CI 72.4–87.5% 78.2–92.5% 21.5–68.1% 97.6–100%
MGIT only
    n/N (%) 107/109 (98.2%) 92/92i (100%) 15/15i (100%) 116/116k (100%)
    95% CI 94.1–99.7% 96.8–100% 81.9–100% 97.5–100%
TB-Biochip (N=104)l
    n/N (%) 69/71 (97.3%) 64/64 (100%) 5/7 (71.4%) 25/32 (78.1%)
    95% CIi 91.0–99.5% 95.4–100% 33.0–94.9% 61.5–89.9%
Note.
n=correct number of tests, compared to the reference standard.
N=total number of tests.
a
Reference standard: positive culture (either LJ and/or MGIT) in same specimen except as noted. For estimation of test performance, NTM were 
considered culture-negative.
b
One had both LJ and MGIT cultures contaminated; one culture result was missing.
c
Two were indeterminate.

















Four cultures were contaminated, one culture result was missing.
f
Four cultures were contaminated.
g
One culture result was missing
h
Two culture results were missing.
i
One culture was contaminated.
k
Seven cultures were contaminated; four culture results were missing.
l
TB-Biochip was only performed at the CTRI laboratory on 104 specimens. A total of 71/104 specimens were MTBC culture-positive (64/71 
smear-positive); 100/104 specimens were from patients with culture-confirmed or final diagnosis of TB and 4/104 specimens were from patients 
with ruled out TB.
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Table 2
Sensitivity, specificity and predictive values of the Xpert and TB-Biochip for detection of RIF resistance with 
culture method as reference (N=109)
Test method and DST reference
standard
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Xpert, direct a
  Reference standard: LJ b
    n/N (%) 45/50 (90.0%) 28/30 (93.3%) 45/47 (95.7%) 28/33 (84.9%)
    95% CI 79.2–96.2% 79.7–98.9% 86.6–99.3% 69.6–94.2%
  Reference standard: MGIT c
    n/N (%) 55/56 (98.2%) 42/44 (95.5%) 55/57 (96.5%) 42/43 (97.7%)
    95% CI 91.5–99.9% 85.8–99.2% 88.9–99.4% 89.1–99.9%
  Reference standard: LJ or MGIT d
    n/N (%) 57/62 (91.9%) 38/39 (97.4%) 57/58 (98.3%) 38/43 (88.4%)
    95% CI 83.0–97.0% 88.0–99.9% 91.8–99.9% 76.1–95.6%
Xpert, concentrated e
  Reference standard: LJ b
    n/N (%) 45/50 (90.0%) 27/29 (93.1%) 45/47 (95.7%) 27/32 (84.4%)
    95% CI 79.2–96.2% 79.0–98.8% 86.6–99.3% 68.7–94.0%
  Reference standard: MGIT c
    n/N (%) 55/56 (98.2%) 40/42 (95.2%) 55/57 (96.5%) 40/41 (97.6%)
    95% CI 91.5–99.9% 85.2–99.2% 88.9–99.4% 88.6–99.9%
  Reference standard: LJ or MGIT d
    n/N (%) 57/62 (91.9%) 36/37 (97.3%) 57/58 (98.3%) 36/41 (87.8%)
    95% CI 83.0–97.0% 87.4–99.9% 91.8–99.9% 75.0–95.4%
TB-Biochip (N=69)f
  Reference standard: LJ
    n/N (%) 40/44 (90.9%) 13/14 (92.9%) 40/41 (97.6%) 13/17 (92.9%)
    95% CI 79.5–97.0% 69.5–99.6% 88.6–99.9% 52.5–92.0%
  Reference standard: MGIT
    n/N (%) 50/50 (100%) 18/19 (94.7%) 50/51 (98.0%) 18/18 (100%)
    95% CI 94.2–100% 76.7–99.7% 90.7–99.9% 84.7–100%
  Reference standard: LJ or MGIT
    n/N (%) 51/55 (92.7%) 14/14 (100%) 51/51 (100%) 14/18 (77.8%)
    95% CI 83.4–97.7% 80.7–100.0% 94.3–100.0% 54.7–92.5%
n=correct number of tests, compared to the reference standard.
N=total number of tests.
LJ = absolute concentration method on LJ medium
a
One hundred one specimens had direct Xpert result for RIF resistance: 58 with RIF resistance and 43 without RIF resistance.
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b
Eighty four specimens had RIF DST result on LJ: 53 with RIF resistance and 31 with RIF susceptibility.
c
One hundred seven specimens had RIF DST result on MGIT: 61 with RIF resistance and 46 with RIF susceptibility.
d
RIF resistance defined as resistance by either LJ and/or MGIT DST methods. RIF susceptibility defined as susceptible by both LJ and MGIT 
methods or by either method when only results from one method were available. One hundred nine specimens had DST results by LJ and/or MGIT 
for RIF: 67 resistant, 42 susceptible.
e
Ninety nine specimens had concentrated Xpert results for RIF: 58 resistant, 41 without RIF resistance.
f
TB-Biochip was performed only at the CTRI laboratory. Sixty nine specimens had TB-Biochip results for RIF resistance: 51 resistant, 18 without 
RIF resistance.
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Table 3












R R R 43 43
R S R 1 1
S R R 1 1
S S R 1 1
R R S 1 1
R S S 4 4
S S S 28 27
N/A R R 11 11
N/A S S 10 9
R N/A R 1 1
N/A N/A S 7 a 6 b
N/A N/A R 7 c 4 d
N/A S N/A 1 2
S S N/A 0 1
N/A N/A N/A 3 7
Note. R=resistant; S=susceptible; N/A=result not available (contamination on LJ or MGIT or “invalid”, “error” result on Xpert).
a
2 of 7 specimens were from cases with TB ruled out;
b
3 of 6 specimens were from cases with TB ruled out;
c
1 of 7 specimens from case with TB ruled out;
d
1 specimen from case with TB ruled out.
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